We are live on ! Find out more
ZOM

Zomedica Corp.

Delisted

ZOM was delisted on the 4th of March, 2025.

97 hedge funds and large institutions have $20.8M invested in Zomedica Corp. in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% less funds holding

Funds holding: 11097 (-13)

29% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 24

46% less capital invested

Capital invested by funds: $38.3M → $20.8M (-$17.5M)

50% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 26

Holders
97
Holders Change
-13
Holders Change %
-11.82%
% of All Funds
1.63%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
17
Reduced
24
Closed
26
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$9.7M +$883K +3,469,211 +9%
BlackRock
2
BlackRock
New York
$2.5M -$526K -2,064,801 -15%
Cambridge Investment Research Advisors
3
Cambridge Investment Research Advisors
Iowa
$2.46M +$1.53K +6,000 +0.1%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$1.96M +$193K +757,146 +9%
State Street
5
State Street
Massachusetts
$735K -$3.92M -15,379,313 -82%
Renaissance Technologies
6
Renaissance Technologies
New York
$552K +$638K +2,507,500 New
BBHC
7
Brown Brothers Harriman & Co
New York
$503K
Northern Trust
8
Northern Trust
Illinois
$369K -$134K -524,557 -24%
GCP
9
GSA Capital Partners
United Kingdom
$280K +$11.3K +44,421 +4%
PWMG
10
Pinnacle Wealth Management Group
Michigan
$258K
Jane Street
11
Jane Street
New York
$238K +$222K +871,646 +414%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$128K -$253 -992 -0.2%
Morgan Stanley
13
Morgan Stanley
New York
$124K -$12.8K -50,388 -8%
Millennium Management
14
Millennium Management
New York
$123K +$100K +394,058 +241%
Qube Research & Technologies (QRT)
15
Qube Research & Technologies (QRT)
United Kingdom
$109K +$126K +496,788 New
Charles Schwab
16
Charles Schwab
California
$76K
VF
17
Virtu Financial
New York
$60K -$135K -530,259 -66%
GT
18
Glenmede Trust
Pennsylvania
$53K +$16K +63,000 +35%
Commonwealth Equity Services
19
Commonwealth Equity Services
Massachusetts
$48K -$547 -2,150 -1%
SCA
20
Snowden Capital Advisors
New York
$42K +$2.8K +11,000 +6%
T. Rowe Price Associates
21
T. Rowe Price Associates
Maryland
$41K
ECM
22
ExodusPoint Capital Management
New York
$38K +$43.7K +171,703 New
Victory Capital Management
23
Victory Capital Management
Texas
$29K -$130K -512,099 -79%
WMA
24
West Michigan Advisors
Michigan
$28K +$10.7K +42,000 +50%
UBS Group
25
UBS Group
Switzerland
$27K -$19.1K -75,043 -38%

ZOM Hedge Fund Activity: Q2 2022 in Review

97 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Zomedica Corp. (ZOM) for Q2 2022, worth a combined $20.8M — down 46% from $38.3M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of ZOM and 13 opened new positions — a net loss of 13 holders — while 24 trimmed existing stakes and 17 added.

The largest buyer was Vanguard Group, adding an estimated $883K. The largest seller was State Street, cutting an estimated $3.92M.

  • 97 institutional investors held Zomedica Corp. (ZOM) as of Q2 2022, down from 110 in Q1 2022.
  • Funds reported $20.8M of Zomedica Corp. stock for Q2 2022, down 46% quarter-over-quarter.
  • 13 funds opened new Zomedica Corp. positions in Q2 2022 and 26 closed out, a net change of -13 holders.
  • The largest Zomedica Corp. buyer in Q2 2022 was Vanguard Group, an estimated $883K added.
  • The largest Zomedica Corp. seller in Q2 2022 was State Street, an estimated $3.92M sold.

Based on aggregated 13F filings for Q2 2022.